Global Precision Cancer Diagnostic Tests Market Size By Type (Imaging, Molecular), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Precision Cancer Diagnostic Tests Market was valued at USD 5.1 billion in 2023 and is projected to reach USD 12.4 billion by 2031, expanding at a CAGR of 11.6% during the forecast period from 2023 to 2031. This growth is propelled by the rising prevalence of various cancers, advancements in molecular diagnostics, and the increasing shift towards personalized medicine. Precision cancer diagnostic tests facilitate early and accurate detection of cancer by leveraging genomics, proteomics, and liquid biopsy techniques, enabling clinicians to tailor treatment plans based on the individual genetic profile of patients.

Drivers

Rising Incidence of Cancer Worldwide

The global cancer burden continues to increase, necessitating more advanced diagnostic solutions for early detection, disease monitoring, and treatment efficacy assessments. This rising prevalence directly boosts the demand for precision diagnostics.

Technological Innovations in Genomics and Proteomics

Next-generation sequencing (NGS), digital PCR, and high-throughput screening technologies are revolutionizing cancer diagnostics by providing highly specific and sensitive assays. These innovations are making tests more accessible and cost-effective.

Shift Toward Personalized Medicine

There is a global trend in oncology toward precision and personalized treatments. Diagnostic tests that can identify genetic mutations and biomarkers critical for selecting targeted therapies are in high demand, driving market growth.

Restraints

High Cost of Advanced Diagnostic Tests

The high development and operational costs of precision diagnostic platforms remain a major barrier, especially in low- and middle-income countries. These costs limit access and implementation across broader healthcare systems.

Regulatory and Reimbursement Challenges

Stringent regulatory pathways and variability in reimbursement policies across different regions can delay product launches and impede the adoption of novel diagnostic tools.

Opportunity

Growing Adoption of Liquid Biopsy Technologies

Liquid biopsies are emerging as a non-invasive, real-time alternative to traditional tissue biopsies. They allow for early detection, treatment monitoring, and recurrence tracking, offering significant growth potential for market players.

Expanding Applications in Companion Diagnostics

The co-development of diagnostic tests with targeted cancer therapies is creating new revenue streams. Companion diagnostics are essential for selecting patients likely to benefit from specific drugs, fueling demand.

Market by System Type Insights

Based on system type, the Genomic Testing Platforms segment dominated the market in 2023, accounting for the largest revenue share. These platforms are crucial for identifying oncogenic mutations, tumor mutational burden, and gene expression profiles. Their role in clinical decision-making and personalized therapy selection ensures continued growth during the forecast period.

Market by End-use Insights

The Hospital and Clinical Laboratories segment emerged as the largest end-user in 2023, driven by increased cancer screening programs, improved infrastructure, and adoption of precision diagnostics in clinical workflows. Moreover, the segment benefits from the integration of molecular pathology and centralized testing services in hospital settings.

Market by Regional Insights

North America led the global market in 2023, supported by high healthcare expenditure, widespread adoption of advanced diagnostic technologies, and the presence of major market players. However, Asia-Pacific is expected to witness the highest CAGR during the forecast period due to increasing awareness, healthcare investments, and growing incidence of cancer in countries like China and India.

Competitive Scenario

Leading players in the Global Precision Cancer Diagnostic Tests Market include Roche Diagnostics, Illumina Inc., Thermo Fisher Scientific, QIAGEN, Guardant Health, Foundation Medicine, Bio-Rad Laboratories, and Agilent Technologies. These companies are focused on strategic partnerships, acquisitions, and the development of AI-powered and multi-omics platforms. Noteworthy developments include:

In 2023, Illumina launched a new sequencing system tailored for rapid oncology diagnostics in community hospitals.

In 2024, QIAGEN expanded its companion diagnostics portfolio with the approval of a new EGFR mutation test for lung cancer.

In 2025, Guardant Health introduced a blood-based multi-cancer detection test entering commercial phase after successful trials.

Scope of Work – Global Precision Cancer Diagnostic Tests Market

Report Metric Details

Market Size (2023) USD 5.1 billion

Projected Market Size (2031) USD 12.4 billion

CAGR (2023–2031) 11.6%

Market Segments By System Type (Genomic, Proteomic, Imaging-Based), By End-use (Hospitals, Diagnostic Labs, Research Centers), By Region

Growth Drivers